Dr. Zulueta on the Application of the LuCED Test for Lung Cancer

Javier Zulueta, MD
Published: Tuesday, Jun 06, 2017



Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.

An additional application for the test is to detect dysplasia, states Zulueta. There is now evidence that chemo-prevention can be achieved in patients who have dysplasia.

This has been shown in phase II trials, explains Zulueta. Previously, in order to diagnose dysplasia there was an invasive test, however, now the LuCED test can provide a non-invasive diagnosis.
 


Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.

An additional application for the test is to detect dysplasia, states Zulueta. There is now evidence that chemo-prevention can be achieved in patients who have dysplasia.

This has been shown in phase II trials, explains Zulueta. Previously, in order to diagnose dysplasia there was an invasive test, however, now the LuCED test can provide a non-invasive diagnosis.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x